DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Recruiting

Phase 3

Obrixtamig & ChemotherapyDAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

Sponsor:

Boehringer Ingelheim

Code:

NCT07544654

Conditions

Extrapulmonary Neuroendocrine Cancer (epNEC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Obrixtamig

Carboplatin

Etoposide

Ventana DLL3 RxDx assay

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-19. This information was provided to ClinicalTrials.gov by Boehringer Ingelheim on 2026-08-06.